International Gynecologic Cancer Society (IGCS) 2018: Meeting report

Published:October 27, 2018DOI:
      The 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS 2018) was held September 14–16, 2018 in collaboration with the Japan Society of Gynecologic Oncology in the beautiful city of Kyoto, Japan. IGCS President Michael Quinn and Japan SGO (JSGO) President Aikou Okamoto, in conjunction with Scientific Program Chair Keiichi Fujiwara and Organizing Program Chair Ikuo Konishi, presented an outstanding program. Dr. Agnes Binagwaho from Rwanda served as the presidential speaker. IGCS awards were presented to Henry Kitchener, MD (UK) for lifetime achievement, Peter Heintz, MD, PhD (Netherlands) for excellence in teaching, Ted Trimble, MD, MPH (US) and Agnes Binagwaho, MD, PhD (Rwanda) for Community Advancement in Resource-Limited Settings.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mileshkin L.R.
        • Narayan K.
        • Moore K.N.
        • et al.
        A phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: outback (ANZGOG0902/GOG0274/RTOG1174).
        J. Clin. Oncol. 2014; 32
        • Coleman R.L.
        • Brady M.F.
        • Herzog T.J.
        • et al.
        Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
        Lancet Oncol. 2017; 18: 779-791
        • Coleman R.L.
        • Enserro D.
        • Spirtos N.M.
        • et al.
        A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): a NRG oncology/gynecologic oncology group (GOG) study.
        J. Clin. Oncol. 2018; 36
        • Coleman R.L.
        • Oza A.M.
        • Lorusso D.
        • et al.
        Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet. 2017; 390: 1949-1961
        • Mirza M.R.
        • Matulonis U.A.
        Niraparib in recurrent ovarian cancer.
        N. Engl. J. Med. 2017; 376: 801-802
        • Pujade-Lauraine E.
        • Ledermann J.A.
        • Selle F.
        • et al.
        Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2017; 18: 1274-1284
        • Swisher E.M.
        • Lin K.K.
        • Oza A.M.
        • et al.
        Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 75-87
        • du Bois A.
        • Floquet A.
        • Kim J.W.
        • et al.
        Incorporation of pazopanib in maintenance therapy of ovarian cancer.
        J. Clin. Oncol. 2014; 32: 3374-3382
        • Kim J.W.
        • Mahner S.
        • Wu L.Y.
        • et al.
        Pazopanib maintenance therapy in east Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian study.
        Int. J. Gynecol. Cancer. 2018; 28: 2-10
        • Hamanishi J.
        • Mandai M.
        • Ikeda T.
        • et al.
        Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.
        J. Clin. Oncol. 2015; 33: 4015-4022
        • Matulonis U.A.
        • Shapira-Frommer R.
        • Santin A.
        • et al.
        Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: interim results from the phase 2 KEYNOTE-100 study.
        J. Clin. Oncol. 2018; 36: 5511
        • Disis M.L.
        • Patel M.R.
        • Pant S.
        • et al.
        Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity.
        J. Clin. Oncol. 2016; 34: 5533
        • Poveda A.M.
        • Selle F.
        • Hilpert F.
        • et al.
        Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial.
        J. Clin. Oncol. 2015; 33: 3836-3838
        • Bohm S.
        • Faruqi A.
        • Said I.
        • et al.
        Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
        J. Clin. Oncol. 2015; 33: 2457-2463
        • Burger R.A.
        • Brady M.F.
        • Bookman M.A.
        • et al.
        Incorporation of bevacizumab in the primary treatment of ovarian cancer.
        N. Engl. J. Med. 2011; 365: 2473-2483
        • Perren T.J.
        • Swart A.M.
        • Pfisterer J.
        • et al.
        A phase 3 trial of bevacizumab in ovarian cancer.
        N. Engl. J. Med. 2011; 365: 2484-2496
        • Burleigh A.
        • Talhouk A.
        • Gilks C.B.
        • et al.
        Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors.
        Gynecol. Oncol. 2015; 138: 141-146